

Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock

Solenn Remy, Morgane Gossez, Alexandre Belot, Jack Hayman, Aurelie

Portefaix, Fabienne Venet, Etienne Javouhey, Guillaume Monneret

▶ To cite this version:

Solenn Remy, Morgane Gossez, Alexandre Belot, Jack Hayman, Aurelie Portefaix, et al.. Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock. Critical Care, 2018, 22 (213), 2 p. 10.1186/s13054-018-2146-2. hal-02266062

HAL Id: hal-02266062 https://hal.science/hal-02266062v1

Submitted on 13 Aug 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

LETTER





Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock

Solenn Remy¹, Morgane Gossez^{2,3}, Alexandre Belot^{4,5}, Jack Hayman², Aurelie Portefaix⁶, Fabienne Venet^{2,3}, Etienne Javouhey¹ and Guillaume Monneret^{2,3,7*}

Keywords: Immune response, Septic shock, Biomarker, Hemophagocytic lymphohistiocytosis

Clinical presentations of hemophagocytic lymphohistiocytosis (HLH) and septic shock share many similarities, including multiple organ dysfunction and overall clinical and biological symptoms. However, these life-threatening conditions require specific and opposing treatments. Currently, no single biomarker is available to differentiate septic shock from HLH at patient admission [1, 2]. HLH is classified as a primary (genetically inherited) or a secondary, i.e., induced by various inflammatory conditions (viral infections, autoimmune processes, lymphoid malignancies, or drug allergies), immune disorder. We report here the case of a young woman with febrile shock which proved to be a HLH caused by drug-induced hypersensitivity syndrome (DIHS). As septic shock was initially suspected, the patient benefited from broad immunological screening during the first week of evolution [3]. Strikingly, this revealed massively increased expression of monocyte human leukocyte antigen-DR (mHLA-DR) at 137,021 ABC (antibody bound per cell), even though expected values in septic shock are usually drastically decreased [3]. In addition, a positive response to increasing doses of corticosteroids was observed over time (Fig. 1). More precisely, while the patient's mHLA-DR expression was measured at 137,021 ABC at admission, it decreased to 38,961 ABC after the introduction of corticosteroids (day

* Correspondence: guillaume.monneret@chu-lyon.fr

Full list of author information is available at the end of the article



3). Following the reactivation of inflammatory processes (day 5), mHLA-DR rose again (66,829 ABC). Finally, mHLA-DR returned to a normal range after increasing corticosteroid doses (20,499 ABC, day 8). All clinical features are provided in Additional file 1.

In the present patient, the extremely increased inaugural mHLA-DR value (i.e., 137,021 ABC) helped to unequivocally exclude a diagnosis of septic shock. Indeed, in our experience (more than 600 septic shock patients monitored over several years), the vast majority of mHLA-DR values measured within the first 3 days after septic shock are reported to be < 30,000 ABC and mostly found below 10,000 ABC (normal values ranged from 15,000 to 40,000 ABC). This agrees with pathophysiology since HLH is secondary to overproduction of interferon- γ (IFN- γ), a cytokine known to be a strong inducer of mHLA-DR expression, whereas sepsis induces downregulation of mHLA-DR expression.

In conclusion, mHLA-DR may discriminate septic shock from HLH at admission despite both situations with multiple organ dysfunction sharing very common clinical and biological features (e.g., sCD25, elevated ferritin levels) [4, 5]. This result obviously needs further assessment in various types of HLH. Upon confirmation, as these two deadly conditions (i.e., septic shock and HLH) would require opposing treatments, mHLA-DR may be of crucial help for clinicians regarding patients' care and management.

© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

²Hospices Civils de Lyon, Immunology Laboratory, E. Herriot Hospital, 69003 Lyon, France

³EA 7426, Pathophysiology of injury-induced immunosuppression (University Claude Bernard Lyon 1, BioMérieux, Hospices Civils de Lyon), E. Herriot Hospital, 69003 Lyon, France




Fig. 1 Time course of mHLA-DR in a HLH patient. *Blue squares* depict mHLA-DR values in the HLH patient. *Red circles* represent pediatric septic shock values [3]. *Gray range* represents interquartile range values obtained previously in healthy children [3]. *Corticosteroids introduced, receiving 2 mg/kg/day; **corticosteroid adjustment to 4 mg/kg/day

Additional file

Additional file 1: Additional online information. (DOCX 27 kb)

Abbreviations

ABC: Antibody bound per cell; DIHS: Drug-induced hypersensitivity syndrome; HLH: Hemophagocytic lymphohistiocytosis; IFN- γ : Interferon- γ ; mHLA-DR: Monocyte human leukocyte antigen-DR

Funding

This work was supported by Hospices Civils de Lyon and University Claude Bernard Lyon 1.

Availability of data and materials

According to the French National Data Protection Commission, we are not authorized to provide the individual clinical data.

Authors' contributions

EJ and GM conceptualized and designed the PedIRIS study and reviewed and revised each draft of the manuscript. SR, AP, and AB participated in patient treatment and reviewed and revised the manuscript. SR, MG, FV, and JH performed biological analysis and reviewed and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This case report belongs to the PedIRIS study. This observational prospective clinical study was approved by our Institutional Review Board (Comité de Protection des Personnes, Lyon Sud-Est II, number 2014–010-2, in accordance with Article L1121–1 of the French Public Health Code). According to legislation in place at the time of the study, this study required only the non-opposition of the study participants (written informed consent was not required). An information leaflet was systematically distributed to holders of parental authority. Participants and/or holders of parental authority could withdraw consent at any time. The study was registered: Pediatric Immune Response to Infectious Shock (PedIRIS), NCT02848144.

Consent for publication

Written informed consent for publication of their clinical details was obtained from the parent of the patient. A copy of the consent form is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Hospices Civils de Lyon, Paediatric Intensive Care Unit, Mother and Children University Hospital, 59 Boulevard Pinel, 69500 Bron, France. ²Hospices Civils de Lyon, Immunology Laboratory, E. Herriot Hospital, 69003 Lyon, France. ³EA 7426, Pathophysiology of injury-induced immunosuppression (University Claude Bernard Lyon 1, BioMérieux, Hospices Civils de Lyon), E. Herriot Hospital, 69003 Lyon, France. ⁴Hospices Civils de Lyon, Paediatric Nephrology, Rheumatology, Dermatology Unit, National Referee Centre for pediatric-onset Rheumatism and autoimmune diseases (RAISE), Mother and Children University Hospital, 59 Boulevard Pinel, 69500 Bron, France. ⁵Université de Lyon, INSERM U1111, CIRI, Lyon, France. ⁶EPICIME-CIC 1407 de Lyon, Inserm, Service de Pharmacologie Clinique, CHU-Lyon, Bron, France. ⁷Cellular Immunology Laboratory, Hôpital E. Herriot – Hospices Civils de Lyon, France. Paulo I. J. Sonder S. Sonder S. Sunderson, Service de Pharmacologie Clinique, CHU-Lyon, Bron, France. ⁷Cellular Immunology Laboratory, Hôpital E. Herriot – Hospices Civils de Lyon, France. Paulo I. J. Sonder S. Sonder Paulo I. J. Sonder V. J. Sonder V.

Received: 20 July 2018 Accepted: 30 July 2018 Published online: 11 September 2018

References

- Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. 2009;10(3):387–92.
- Machowicz R, Janka G. Similar but not the same: differential diagnosis of HLH and sepsis. Crit Rev Oncol Hematol. 2017;114:1–12.
- Remy S, Kolev-Descamps K. Occurrence of marked sepsis-induced immunosuppression in pediatric septic shock: a pilot study. Ann Intensive Care. 2018;8(1):36.
- Rosario C, Zandman-Goddard G. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.
- Møller HJ, Moestrup S. Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med. 2006; 34(10):2561–6.